Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab plus atezolizumab (TA) versus placebo plus atezolizumab (PA) as first-line treatment for PD-L1+NSCLC
No Thumbnail Available
Identifiers
Date
2021-12-10
Authors
Cho, B. C.
Rodriguez-Abreu, D.
Hussein, M.
Cobo, M.
Patel, A.
Secen, N.
Gerstner, G.
Kim, D-W.
Lee, Y-G.
Su, W-C.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
